Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis-osteopontin as a potential marker of clinical severity

Levente Szalardy, Denes Zadori, Mihaela Simu, K. Bencsik, L. Vécsei, P. Klivényi

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

Biomarkers capable of predicting the clinical course and the rate of disease progression in multiple sclerosis are currently unavailable. Our objective was to examine if the levels of proteins associated with axonal and neuronal degeneration (Tau, p-Tau and β-amyloid1-42) and T-cell-mediated autoimmunity (osteopontin) are altered in the cerebrospinal fluid (CSF) of MS patients, and to assess their potential in reflecting the clinical severity and predicting the progression and clinical evolution of early MS. The CSF samples collected from patients presenting with different clinical forms of MS were evaluated by enzyme-linked immunosorbent assays. The patients were regularly followed-up and their clinical status was re-evaluated 5 years after sampling. The results demonstrated that while CSF levels of Tau, p-Tau and β-amyloid1-42 did not differ between MS and Control groups, the levels of osteopontin were significantly elevated in MS patients. This increase was associated with the presence of a relapse and correlated with clinical severity, which findings were independent of age and blood-CSF barrier function. However, none of the examined protein levels differed significantly between groups with different clinical evolutions and no positive correlations with clinical progression could be detected. We conclude that Tau, p-Tau and β-amyloid1-42 are inappropriate as biomarkers in MS. This is the first report on CSF osteopontin as an independent marker of clinical severity in definite MS.

Original languageEnglish
Pages (from-to)38-42
Number of pages5
JournalJournal of the Neurological Sciences
Volume331
Issue number1-2
DOIs
Publication statusPublished - Sep 15 2013

Fingerprint

Osteopontin
Multiple Sclerosis
Cerebrospinal Fluid
Biomarkers
Autoimmunity
Disease Progression
Proteins
Enzyme-Linked Immunosorbent Assay
T-Lymphocytes
Recurrence
Control Groups

Keywords

  • Beta-amyloid
  • Biomarkers
  • Cerebrospinal fluid
  • ELISA
  • Multiple sclerosis
  • Osteopontin
  • Tau

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

@article{9970a2053f5c4325bfe77517e1778027,
title = "Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis-osteopontin as a potential marker of clinical severity",
abstract = "Biomarkers capable of predicting the clinical course and the rate of disease progression in multiple sclerosis are currently unavailable. Our objective was to examine if the levels of proteins associated with axonal and neuronal degeneration (Tau, p-Tau and β-amyloid1-42) and T-cell-mediated autoimmunity (osteopontin) are altered in the cerebrospinal fluid (CSF) of MS patients, and to assess their potential in reflecting the clinical severity and predicting the progression and clinical evolution of early MS. The CSF samples collected from patients presenting with different clinical forms of MS were evaluated by enzyme-linked immunosorbent assays. The patients were regularly followed-up and their clinical status was re-evaluated 5 years after sampling. The results demonstrated that while CSF levels of Tau, p-Tau and β-amyloid1-42 did not differ between MS and Control groups, the levels of osteopontin were significantly elevated in MS patients. This increase was associated with the presence of a relapse and correlated with clinical severity, which findings were independent of age and blood-CSF barrier function. However, none of the examined protein levels differed significantly between groups with different clinical evolutions and no positive correlations with clinical progression could be detected. We conclude that Tau, p-Tau and β-amyloid1-42 are inappropriate as biomarkers in MS. This is the first report on CSF osteopontin as an independent marker of clinical severity in definite MS.",
keywords = "Beta-amyloid, Biomarkers, Cerebrospinal fluid, ELISA, Multiple sclerosis, Osteopontin, Tau",
author = "Levente Szalardy and Denes Zadori and Mihaela Simu and K. Bencsik and L. V{\'e}csei and P. Kliv{\'e}nyi",
year = "2013",
month = "9",
day = "15",
doi = "10.1016/j.jns.2013.04.024",
language = "English",
volume = "331",
pages = "38--42",
journal = "Journal of the Neurological Sciences",
issn = "0022-510X",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Evaluating biomarkers of neuronal degeneration and neuroinflammation in CSF of patients with multiple sclerosis-osteopontin as a potential marker of clinical severity

AU - Szalardy, Levente

AU - Zadori, Denes

AU - Simu, Mihaela

AU - Bencsik, K.

AU - Vécsei, L.

AU - Klivényi, P.

PY - 2013/9/15

Y1 - 2013/9/15

N2 - Biomarkers capable of predicting the clinical course and the rate of disease progression in multiple sclerosis are currently unavailable. Our objective was to examine if the levels of proteins associated with axonal and neuronal degeneration (Tau, p-Tau and β-amyloid1-42) and T-cell-mediated autoimmunity (osteopontin) are altered in the cerebrospinal fluid (CSF) of MS patients, and to assess their potential in reflecting the clinical severity and predicting the progression and clinical evolution of early MS. The CSF samples collected from patients presenting with different clinical forms of MS were evaluated by enzyme-linked immunosorbent assays. The patients were regularly followed-up and their clinical status was re-evaluated 5 years after sampling. The results demonstrated that while CSF levels of Tau, p-Tau and β-amyloid1-42 did not differ between MS and Control groups, the levels of osteopontin were significantly elevated in MS patients. This increase was associated with the presence of a relapse and correlated with clinical severity, which findings were independent of age and blood-CSF barrier function. However, none of the examined protein levels differed significantly between groups with different clinical evolutions and no positive correlations with clinical progression could be detected. We conclude that Tau, p-Tau and β-amyloid1-42 are inappropriate as biomarkers in MS. This is the first report on CSF osteopontin as an independent marker of clinical severity in definite MS.

AB - Biomarkers capable of predicting the clinical course and the rate of disease progression in multiple sclerosis are currently unavailable. Our objective was to examine if the levels of proteins associated with axonal and neuronal degeneration (Tau, p-Tau and β-amyloid1-42) and T-cell-mediated autoimmunity (osteopontin) are altered in the cerebrospinal fluid (CSF) of MS patients, and to assess their potential in reflecting the clinical severity and predicting the progression and clinical evolution of early MS. The CSF samples collected from patients presenting with different clinical forms of MS were evaluated by enzyme-linked immunosorbent assays. The patients were regularly followed-up and their clinical status was re-evaluated 5 years after sampling. The results demonstrated that while CSF levels of Tau, p-Tau and β-amyloid1-42 did not differ between MS and Control groups, the levels of osteopontin were significantly elevated in MS patients. This increase was associated with the presence of a relapse and correlated with clinical severity, which findings were independent of age and blood-CSF barrier function. However, none of the examined protein levels differed significantly between groups with different clinical evolutions and no positive correlations with clinical progression could be detected. We conclude that Tau, p-Tau and β-amyloid1-42 are inappropriate as biomarkers in MS. This is the first report on CSF osteopontin as an independent marker of clinical severity in definite MS.

KW - Beta-amyloid

KW - Biomarkers

KW - Cerebrospinal fluid

KW - ELISA

KW - Multiple sclerosis

KW - Osteopontin

KW - Tau

UR - http://www.scopus.com/inward/record.url?scp=84882453644&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882453644&partnerID=8YFLogxK

U2 - 10.1016/j.jns.2013.04.024

DO - 10.1016/j.jns.2013.04.024

M3 - Article

C2 - 23706476

AN - SCOPUS:84882453644

VL - 331

SP - 38

EP - 42

JO - Journal of the Neurological Sciences

JF - Journal of the Neurological Sciences

SN - 0022-510X

IS - 1-2

ER -